MX375864B - Esteroides de 5.beta-6-alquil-7-hidroxi-3-ona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr) - Google Patents

Esteroides de 5.beta-6-alquil-7-hidroxi-3-ona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr)

Info

Publication number
MX375864B
MX375864B MX2017006564A MX2017006564A MX375864B MX 375864 B MX375864 B MX 375864B MX 2017006564 A MX2017006564 A MX 2017006564A MX 2017006564 A MX2017006564 A MX 2017006564A MX 375864 B MX375864 B MX 375864B
Authority
MX
Mexico
Prior art keywords
farnesoid
fxr
steroids
receptor
beta
Prior art date
Application number
MX2017006564A
Other languages
English (en)
Spanish (es)
Other versions
MX2017006564A (es
Inventor
Alexander Weymouth-Wilson
James Boydell
Laura Wallis
Montserrat Shelbourne
Nathan Bartlett
Zofia Komsta
Original Assignee
Nzp Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1420594.2A external-priority patent/GB201420594D0/en
Priority claimed from GBGB1420593.4A external-priority patent/GB201420593D0/en
Priority claimed from GBGB1505674.0A external-priority patent/GB201505674D0/en
Application filed by Nzp Uk Ltd filed Critical Nzp Uk Ltd
Publication of MX2017006564A publication Critical patent/MX2017006564A/es
Publication of MX375864B publication Critical patent/MX375864B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2017006564A 2014-11-19 2015-11-19 Esteroides de 5.beta-6-alquil-7-hidroxi-3-ona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr) MX375864B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1420594.2A GB201420594D0 (en) 2014-11-19 2014-11-19 Compounds
GBGB1420593.4A GB201420593D0 (en) 2014-11-19 2014-11-19 Compounds
GBGB1505674.0A GB201505674D0 (en) 2015-04-01 2015-04-01 Compounds
PCT/GB2015/053517 WO2016079518A1 (en) 2014-11-19 2015-11-19 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators

Publications (2)

Publication Number Publication Date
MX2017006564A MX2017006564A (es) 2018-01-26
MX375864B true MX375864B (es) 2025-03-07

Family

ID=54704020

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006564A MX375864B (es) 2014-11-19 2015-11-19 Esteroides de 5.beta-6-alquil-7-hidroxi-3-ona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr)

Country Status (14)

Country Link
US (1) US10131688B2 (enExample)
EP (1) EP3221332B1 (enExample)
JP (1) JP6724004B2 (enExample)
KR (1) KR102526632B1 (enExample)
CN (1) CN107108687B (enExample)
CA (1) CA2968301C (enExample)
DK (1) DK3221332T3 (enExample)
EA (1) EA033445B1 (enExample)
ES (1) ES2733643T3 (enExample)
HK (1) HK1244285B (enExample)
MX (1) MX375864B (enExample)
PL (1) PL3221332T3 (enExample)
TW (1) TWI686400B (enExample)
WO (1) WO2016079518A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017010319B1 (pt) 2014-11-19 2023-04-11 NZP UK Limited Esteroides 6-alquil-7-hidróxi-4-en-3-ona e processo para a preparação dos mesmos
MX381239B (es) 2014-11-19 2025-03-12 Nzp Uk Ltd Esteroides de 6.alfa.-alquil-6,7-diona como intermedios para la producción de moduladores esteroideos del receptor x farnesoide (fxr).
PL3221333T3 (pl) 2014-11-19 2020-01-31 NZP UK Limited Steroidy, 6.alfa-alkilo-3,7-diony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr
WO2017111979A1 (en) * 2015-12-22 2017-06-29 Intercept Pharmaceuticals, Inc. Polymorphic crystalline forms of obeticholic acid
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608779D0 (en) * 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
CN106279331B (zh) * 2016-07-27 2019-06-14 宋火良 胆酸类肝病治疗药物
EP3431486A1 (en) 2017-07-18 2019-01-23 Bionice, S.L.U. Process and intermediates for the synthesis of obeticholic acid and derivatives thereof
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
CN111138509B (zh) * 2018-11-02 2022-12-06 东莞东阳光药物研发有限公司 奥贝胆酸的制备方法
CN113135970B (zh) * 2020-01-20 2024-11-22 成都贝诺科成生物科技有限公司 一种具有抗芽孢活性的化合物及其药用组合物

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2624748A (en) 1950-09-09 1953-01-06 Upjohn Co Bisnorchola-4, 6-dien-3-one-22-al
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
ATE156158T1 (de) 1992-04-14 1997-08-15 Cornell Res Foundation Inc Makromoleküle auf basis von dendritischen polymeren und verfahren zur herstellung
AU6392894A (en) 1993-02-26 1994-09-14 Magainin Pharmaceuticals, Inc. Chemical synthesis of squalamine
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
AU2002308295B2 (en) 2001-03-12 2007-08-23 Intercept Pharmaceuticals, Inc. Steroids as agonists for FXR
US20090062256A1 (en) 2001-06-01 2009-03-05 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
EP1446438A2 (en) 2001-11-07 2004-08-18 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
ITMI20050912A1 (it) * 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
JP2007210888A (ja) * 2006-01-12 2007-08-23 Mitsubishi Chemicals Corp ステロイド化合物の製造方法
JP2010517931A (ja) 2006-02-14 2010-05-27 インターセプト ファーマシューティカルズ， インコーポレイテッド Ｆｘｒ媒介性の疾患または状態の予防または治療用のｆｘｒリガンドとしての胆汁酸誘導体
PL2040713T3 (pl) 2006-06-27 2014-11-28 Intercept Pharmaceuticals Inc Pochodne kwasów żółciowych jako ligandy FXR do zapobiegania lub leczenia chorób lub stanów, w których pośredniczy FXR
AU2008209566C1 (en) 2007-01-19 2013-02-14 Intercept Pharmaceuticals, Inc. 23-substituted bile acids as TGR5 modulators and methods of use thereof
AU2009276507B2 (en) * 2008-07-30 2015-11-19 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
CA2744189C (en) 2008-11-19 2016-10-11 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
JP5639073B2 (ja) * 2008-11-19 2014-12-10 インターセプト ファーマシューティカルズ， インコーポレイテッド Ｔｇｒ５モジュレーターおよびその使用方法
US8829213B2 (en) 2009-07-29 2014-09-09 The University Of Chicago Liver X receptor agonists
SG10201607230SA (en) 2012-06-19 2016-10-28 Intercept Pharmaceuticals Inc Preparation, Uses And Solid Forms Of Obeticholic Acid
SMT201700602T1 (it) 2012-10-26 2018-03-08 Intercept Pharmaceuticals Inc Processo per la preparazione di derivati dell’acido biliare
RU2693382C2 (ru) * 2012-11-28 2019-07-02 Интерсепт Фармасьютикалз, Инк. Лечение заболевания дыхательной системы
US20140206657A1 (en) 2013-01-18 2014-07-24 City Of Hope Bile acid analog tgr5 agonists
PT3360882T (pt) 2013-05-14 2021-02-12 Intercept Pharmaceuticals Inc Derivados de 11-hidroxilo substituídos em 6 de ácidos biliares e conjugados de aminoácidos dos mesmos como moduladores do recetor farnesoide x
RU2015155590A (ru) 2013-05-24 2017-06-29 Нестек С.А. Путеспецифичные маркеры для диагностики синдрома раздраженного кишечника
WO2015183794A1 (en) 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
JP6820253B2 (ja) 2014-05-29 2021-01-27 バール ファーマシューティカルズ ソチエタ レスポンサビリタ リミタータ Ｆｘｂ及びｔｇｒ５／ｇｐｂａｒ１介在性疾患の治療及び／又は予防に使用するためのコラン誘導体
HK1243930A1 (zh) 2014-11-06 2018-07-27 英安塔制药有限公司 作爲fxr/tgr5激动剂的胆汁酸类似物和其使用方法
PL3221333T3 (pl) 2014-11-19 2020-01-31 NZP UK Limited Steroidy, 6.alfa-alkilo-3,7-diony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
MX381239B (es) 2014-11-19 2025-03-12 Nzp Uk Ltd Esteroides de 6.alfa.-alquil-6,7-diona como intermedios para la producción de moduladores esteroideos del receptor x farnesoide (fxr).
BR112017010319B1 (pt) 2014-11-19 2023-04-11 NZP UK Limited Esteroides 6-alquil-7-hidróxi-4-en-3-ona e processo para a preparação dos mesmos
WO2016086134A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
SG11201703997XA (en) 2014-11-26 2017-06-29 Enanta Pharm Inc Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
CN106279328A (zh) 2015-05-20 2017-01-04 重庆药友制药有限责任公司 一种制备6α-烷基鹅去氧胆酸的方法
AU2016280806B2 (en) 2015-06-19 2021-01-28 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
CN106397522A (zh) 2015-07-31 2017-02-15 中国人民解放军军事医学科学院毒物药物研究所 3,7‑二（叔丁基二甲基硅基氧基）‑6‑烯‑5β‑胆烷‑24‑酸甲酯
CN106478759A (zh) 2015-08-31 2017-03-08 陕西合成药业股份有限公司 奥贝胆酸衍生物及其制备方法和用途
CN106478756A (zh) 2015-09-02 2017-03-08 中美华世通生物医药科技（武汉）有限公司 Oca-e单晶及其制备方法和用途
CN106518946A (zh) 2015-09-10 2017-03-22 上海迪诺医药科技有限公司 磺酰脲衍生物、其药物组合物及应用

Also Published As

Publication number Publication date
EP3221332A1 (en) 2017-09-27
DK3221332T3 (da) 2019-07-29
EA201790881A8 (ru) 2019-07-31
PL3221332T3 (pl) 2019-10-31
US10131688B2 (en) 2018-11-20
KR20170099895A (ko) 2017-09-01
JP2017538691A (ja) 2017-12-28
HK1244285B (en) 2020-06-05
EP3221332B1 (en) 2019-04-24
TW201629081A (zh) 2016-08-16
ES2733643T3 (es) 2019-12-02
US20170320907A1 (en) 2017-11-09
CA2968301C (en) 2023-05-16
TWI686400B (zh) 2020-03-01
EA033445B1 (ru) 2019-10-31
MX2017006564A (es) 2018-01-26
EA201790881A1 (ru) 2017-11-30
CN107108687B (zh) 2019-10-29
WO2016079518A1 (en) 2016-05-26
CA2968301A1 (en) 2016-05-26
JP6724004B2 (ja) 2020-07-15
CN107108687A (zh) 2017-08-29
KR102526632B1 (ko) 2023-04-27

Similar Documents

Publication Publication Date Title
MX375863B (es) Esteroides de 6-alquil-7-hidroxi-4-en-3-ona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr)
MX375864B (es) Esteroides de 5.beta-6-alquil-7-hidroxi-3-ona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr)
MX375865B (es) Esteroides de 6.alfa-alquil-3,7-diona como intermedios para la produccion de moduladores esteroideos del receptor x farnesoide (fxr).
MX381239B (es) Esteroides de 6.alfa.-alquil-6,7-diona como intermedios para la producción de moduladores esteroideos del receptor x farnesoide (fxr).
JOP20190022B1 (ar) ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري
MX2020004024A (es) Derivados del colano para uso en el tratamiento y/o prevencion de enfermedades en las que intervienen el fxr y el tgr5/gpbar1.
PH12018500177A1 (en) Compositions useful for treating disorders related to kit and pdfgr
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
GT201500138A (es) Novedososo derivados de bencimidazol como antagonistas de ep4
EA201992183A3 (ru) Синтез полициклических карбамоилпиридоновых соединений
DOP2015000054A (es) Derivados de c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
CO2017001884A2 (es) Polimorfos de selinexor
UY34472A (es) Derivados modificados de 4-fenil-piridina
BR112017012272A2 (pt) derivados de 2-anilinopirimidina como moduladores de egfr
FR3024465B1 (fr) Caracterisation de micro-organismes par maldi-tof
MX2015016825A (es) Compuestos de pirazol como moduladores del receptor de hormona estimuladora de foliculos y sus usos.
MX2017005578A (es) Métodos de administración de composiciones de amantadina.
MX2016000551A (es) Proceso novedoso para la preparacion de pirrolidina-dionas espiroheterociclicas.
IN2015CH01182A (enExample)
MX389099B (es) Proceso para la preparación de 3-cloro-2-vinilfenilsulfonatos.

Legal Events

Date Code Title Description
FG Grant or registration